Andrew James Doyle

Andrew James Doyle

Auto-generated profile, based on publicly available information

Andrew James Doyle

Department of Haemostasis & Thrombosis Guy's & St Thomas' NHS Foundation Trust London UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Thrombosis Research
Verified
Journal Article
Closed access
MDMichael J.R. Desborough
Michael J.R. Desborough
ADAndrew J. Doyle
Andrew J. Doyle
AGAlexandra Griffiths
Alexandra Griffiths
ARAndrew Retter
Andrew Retter
KBKaren Breen
Karen Breen
BHBeverley Jane Hunt
Beverley Jane Hunt

19 May 2021 in Leukemia
Verified
Journal Article
Closed access
PDF file
TBTiziano Barbui
Tiziano Barbui
Valerio De StefanoValerio De Stefano
Valerio De Stefano
ACAlessandra Carobbio
Alessandra Carobbio
AIAlessandra Iurlo
Alessandra Iurlo
AAAlberto Alvarez-Larran
Alberto Alvarez-Larran
JMJohn Mascarenhas
John Mascarenhas

19 January 2023 in Blood
Verified
Journal Article
Closed access
PDF file
ADAndrew James Doyle
Andrew James Doyle
MSMatthew James Stubbs
Matthew James Stubbs
TDTina Dutt
Tina Dutt
WLWill Lester
Will Lester
WTWill Thomas
Will Thomas
MSMarie Scully
Marie Scully
Disease relapse is recognized as a risk in immune-mediated thrombotic thrombocytopenic purpura (iTTP) after treatment of the acute presenting episode. Identification of patients at risk of relapse and its patterns are yet to be clearly established. We reviewed patients with iTTP having had >3 years of follow-up over 10 years in the United Kingdom to identify patient characteristics for relapse, assess relapse rates and patterns, and response to anti-CD20 therapy in those with a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) relapses (ADAMTS13 activity of 20%. Anti-CD20 therapy was demonstrated to be an effective long-term treatment regardless of relapse pattern and there was no loss of this treatment response after subsequent treatment episodes.

17 April 2022 in British Journal of Haematology
Verified
Journal Article
Closed access
ADAndrew J. Doyle
Andrew J. Doyle
MSMatthew J. Stubbs
Matthew J. Stubbs
WLWill Lester
Will Lester
WTWilliam Thomas
William Thomas
JWJohn‐Paul Westwood
John‐Paul Westwood
MSMarie Scully
Marie Scully

3 February 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
NCNATALIA CURTO-GARCIA
NATALIA CURTO-GARCIA
ADAndrew J. Doyle
Andrew J. Doyle
KBKaren A. Breen
Karen A. Breen
DMDonal P. McLornan
Donal P. McLornan
DRDeepti H. Radia
Deepti H. Radia
CHClaire N. Harrison
Claire N. Harrison
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

24 September 2020 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
JZJoe Zhang
Joe Zhang
BMBlair Merrick
Blair Merrick
GCGenex L. Correa
Genex L. Correa
LCLuigi Camporota
Luigi Camporota
ARAndrew Retter
Andrew Retter
CMChristopher I.S. Meadows
Christopher I.S. Meadows
Background: The use of veno-venous extracorporeal membrane oxygenation (VV-ECMO) in severe hypoxaemic respiratory failure from coronavirus disease 2019 (COVID-19) has been described, but reported utilisation and outcomes are variable, and detailed information on patient characteristics is lacking. We aim to report clinical characteristics, management and outcomes of COVID-19 patients requiring VV-ECMO, admitted over 2 months to a high-volume centre in the UK.Methods: Patient information, including baseline characteristics and clinical parameters, was collected retrospectively from electronic health records for COVID-19 VV-ECMO admissions between 3 March and 2 May 2020. Clinical management is described. Data are reported for survivors and nonsurvivors.Results: We describe 43 consecutive patients with COVID-19 who received VV-ECMO. Median age was 46 years (interquartile range 35.5–52.5) and 76.7% were male. Median time from symptom onset to VV-ECMO was 14 days (interquartile range 11–17.5). All patients underwent computed tomography imaging, revealing extensive pulmonary consolidation in 95.3%, and pulmonary embolus in 27.9%. Overall, 79.1% received immunomodulation with methylprednisolone for persistent maladaptive hyperinflammatory state. Vasopressors were used in 86%, and 44.2% received renal replacement therapy. Median duration on VV-ECMO was 13 days (interquartile range 8–20). 14 patients died (32.6%) and 29 survived (67.4%) to hospital discharge. Nonsurvivors had significantly higher d-dimer (38.2versus9.5 mg·L−1, fibrinogen equivalent units; p=0.035) and creatinine (169versus73 μmol·L−1; p=0.022) at commencement of VV-ECMO.Conclusions: Our data support the use of VV-ECMO in selected COVID-19 patients. The cohort was characterised by high degree of alveolar consolidation, systemic inflammation and intravascular thrombosis.